EVREA-Phage: Phage therapy against Enterococcus faecium
Antibiotic resistance is increasing at an alarming rate worldwide. New treatment options are urgently needed. Due to their specificity toward bacterial hosts, bacteriophages are a promising alternative or adjunct therapeutic option to conventional antibiotics. Their specificity and lack of adverse side effects make phages important objects in biomedicine research. Among the most critical bacterial pathogens in clinical settings are vancomycin-resistant enterococci (VRE), with Enterococcus faecium (VREfm) being of significance. Launched in July 2022, the EVREA-Phage project, aims to enable phage therapy for the reduction of intestinal VRE colonization, particularly in immunocompromised patients.
Immunosuppressed patients often show a typical excessive intestinal colonisation by the bacterium Enterococcus faecium. In the case of excessive colonisation, the actually harmless "intestinal inhabitant" can lead to intestinal cell damage with subsequent bloodstream infection, for example during the administration of chemotherapeutics.
In the EVREA-Phage project (Eradication of intestinal vancomycin-resistant Enterococcus faecium (VRE) using oral phage therapy), a selection is made from a large number and variety of phages that are specifically directed against the bacterium Enterococcus faecium, via numerous tests, of a few that act most efficiently against these target bacteria. After intensive preclinical investigations in a new in vitro intestinal model at the University Hospital Bonn and an in vivo mouse model at the Helmholtz Centre for Infection Research in Braunschweig, selected phages will be combined to form an efficient cocktail against VRE. This cocktail should be able to cover and kill as broad a spectrum of clinical patient strains of Enterococcus faecium as possible. The isolation of new phages against an extensive panel of bacteria is carried out in the phage laboratory of the Leibniz Institute DSMZ. The clinical isolates are mostly from the DZIF studies AEGON and R-Net.
The EVREA phage project is also the subject of the DZIF article in issue #1/2024 of the German-language DZG magazine SYNERGIE.